English Papers
英文論文
2025
- Yonese I, Takemura K, Yuasa T, Amori G, Inamura K, Yonese J. Clinical outcomes of patients with metastatic fumarate hydratase-deficient renal cell carcinoma: A single-center case series. Int J Urol, doi: 10.1111/iju.70000, 2025
- Amano Y, Hasegawa M, Kihara A, Matsubara D, Fukushima N, Nishino H, Mori Y, Inamura K, Niki T. Clinicopathological and prognostic significance of stromal p16 and p53 expression in oral squamous cell carcinoma. Ann Diagn Pathol, 75, 152439, 2025
2024
- Ohmoto A, Shigematsu Y, Saito R, Dobashi A, Fujiwara Y, Togashi Y, Yonese J, Inamura K, Takahashi S. Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma/paraganglioma. Virchows Arch, doi: 10.1007/s00428-024-04009-x, 2024
- Pan Y, Jin X, Hong J, Wang Y, Xu H, Lin J, Zhang Y, Yin K, Zhang J, Inamura K, Liu D, Li F, Zeng J. Blood biomarkers to predict the efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer patients. Transl Lung Cancer Res, 13:2773-2786, 2024
- Shigematsu Y, Kanda H, Takahashi Y, Takeuchi K, Inamura K. Relationships between tumor CD147 expression, tumor-infiltrating lymphocytes, and oncostatin M in hepatocellular carcinoma. Virchows Arch, doi: 10.1007/s00428-024-03939-w, 2024
- Shigematsu Y, Saito R, Amori G, Kanda H, Takahashi Y, Takeuchi K, Takahashi S, Inamura K. Fusobacterium nucleatum, immune responses, and metastatic organ diversity in colorectal cancer liver metastasis. Cancer Sci, doi: 10.1111/cas.16315, 2024
- Shigematsu Y, Saito R, Kanda H, Takahashi Y, Takeuchi K, Takahashi S, Inamura K. Inverse Correlation between pks-Carrying Escherichia coli Abundance in Colorectal Cancer Liver Metastases and the Number of Organs Involved in Recurrence. Cancers, 16, 3003, 2024
- Kitahama K, Shigematsu Y, Amori G, Sugawara E, Yonese J, Shibahara J, Takeuchi K, Inamura K. RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder. Am J Surg Pathol, 48, 458-464, 2024
- Yonese I, Numao N, Inamura K, Yoneoka Y, Fujiwara R, Yasuda Y, Oguchi T, Yamamoto S, Yuasa T, Yonese J. A case of neoadjuvant chemotherapy-resistant muscle-invasive bladder cancer that markedly responded to pembrolizumab before conversion radical cystectomy. IJU Case Rep, 7, 64-67, 2024
- Shigematsu Y, Tanaka K, Amori G, Kanda H, Takahashi Y, Takazawa Y, Takeuchi K, Inamura K. Potential involvement of oncostatin M in the immunosuppressive tumor immune microenvironment in hepatocellular carcinoma with vessels encapsulating tumor clusters. Hepatol Res, 54, 368-381, 2024
- Ninomiya H, Sato Y, Inamura K, Dobashi A, Takeuchi K, Mitani H, Mun M, Nishio M, Ishikawa Y. Neuroendocrine and squamous cell phenotypes of NUT carcinoma are potential diagnostic pitfalls that discriminating it from mimickers, such as small cell and squamous cell carcinoma. Diagn Pathol, 19, 27, 2024
- Kato S, Shigematsu Y, Saito R, Ito H, Inamura K. Schistosoma japonicum-related hepatitis: potential contributor to hepatocellular carcinoma. Qjm, doi: 10.1093/qjmed/hcae116, 2024
- Chen J, He G, Cai D, Giovannetti E, Inamura K, Liu S, Ma W. Lactic acid: a narrative review of a promoter of the liver cancer microenvironment. J Gastrointest Oncol, 15, 1282-1296, 2024
2023
- Sugawara E, Shigematsu Y, Amori G, Sugita K, Yonese J, Takeuchi K, Inamura K. CDX2- and PAX8-Expressing Subtypes in Female Urethral Adenocarcinoma: Pathogenesis Insights Through Immunohistochemical and Morphological Analyses. Diagnostics, in press, 2023
- Shigematsu Y, Inamura K. High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma. JAMA Oncol, 9, 725, 2023
- Shigematsu Y, Inamura K. Machine Learning-Based Treatment Allocation for Recurrent Hepatocellular Carcinoma. JAMA Surg, doi: 10.1001/jamasurg.2023.1673, 2023
- Shigematsu Y, Amori G, Tanaka K, Kitahama K, Kanda H, Takahashi Y, Takazawa Y, Takeuchi K,Inamura K. MHC class I loss is associated with biliary/progenitor cell features and "cold" tumor-immune microenvironment in hepatocellular carcinoma. Virchows Arch, doi: 10.1007/s00428-023-03568-9, 2023
- Oki R, Urasaki T, Ueki A,Inamura K, Komai Y, Takahashi S, Yonese J, Yuasa T. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome. IJU Case Rep, 6, 33-36, 2023
- Murai H, Kodama T, Maesaka K, Tange S, Motooka D, Suzuki Y, Shigematsu Y, Inamura K, Mise Y, Saiura A, Ono Y, Takahashi Y, Kawasaki Y, Iino S, Kobayashi S, Idogawa M, Tokino T, Hashidate-Yoshida T, Shindou H, Miyazaki M, Imai Y, Tanaka S, Mita E, Ohkawa K, Hikita H, Sakamori R, Tatsumi T, Eguchi H, Morii E, Takehara T. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology, 77, 77-91, 2023
- Mima K, Hamada T, Inamura K, Baba H, Ugai T, Ogino S. The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities. Gut Microbes, 15, 2269623, 2023
- Koyama K, Inamura K. Tumor-resident intracellular bacteria benefit metastasis. Annals of Translational Medicine, doi: 10.21037/atm-22-6209, 2023
- Inamura K, Shigematsu Y. Is machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images associated with outcomes of immunotherapy in patients with NSCLC? J Thorac Dis, 15, 2882-2884, 2023
- Inamura K. Oral–Gut Microbiome Crosstalk in Cancer. Cancers, 15, 3396, 2023
- Inamura K. Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond. J Thorac Oncol, in press, 2023
- Inamura K. Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC. J Thorac Oncol, in press, 2023
- Inamura K. Beyond Bacteria: Fungi in the Tumor Microbiome. Cancers (Basel), 15, 572, 2023
- Inamura K. Screening for Prostate Cancer. N Engl J Med, 389, 93, 2023
- Aoki Y, Inoue Y, Sasahira N, Ono M, Inamura K, Kataoka A, Takano T, Kanao H, Watanabe M. Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case report. Oncol Lett, 26, 450, 2023
- Amori G, Sugawara E, Inamura K. Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond. J Thorac Oncol, 18, e134-e135, 2023
2022
- Sugawara E, Koyama K, Inamura K. Molecular Characterization of Upper Tract Urothelial Carcinoma for Precision Therapeutics and Non-invasive Diagnostics. Curr Genomics, 23, 2-4, 2022
- Shigematsu Y, Nakano K, Uchibori K, Inamura K. EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenocarcinoma. J Thorac Oncol, 17, 1318-1322, 2022
- Shigematsu Y, Kanda H, Amori G, Takahashi Y, Takazawa Y, Inamura K. Nonalcoholic non-virus-related hepatocellular carcinoma arising from nonsteatotic liver: Clinical and pathological features. Medicine (Baltimore), 101, e28746, 2022
- Shigematsu Y, Amori G, Kanda H, Takahashi Y, Takazawa Y, Takeuchi K, Inamura K. Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. Virchows Arch, 481, 253-263, 2022
- Ninomiya H,Inamura K, Mun M, Nishio M, Ishikawa Y. Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma. JTO Clin Res Rep, 3, 100293, 2022
- Kunieda J, Yamashita K, Togashi Y, Baba S, Sakata S, IInamura K, Ae K, Matsumoto S, Machinami R, Kitagawa M, Takeuchi K. High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis. Cancer Sci, 113, 1078-1089, 2022
- Ishii S, Takamatsu M, Ninomiya H, Inamura K, Horai T, Iyoda A, Honma N, Hoshi R, Sugiyama Y, Yanagitani N, Mun M, Abe H, Mikami T, Takeuchi K. Machine learning-based gene alteration prediction model for primary lung cancer using cytologic images. Cancer Cytopathol, 130, 812-823, 2022
- Inamura K, Shigematsu Y. The need to optimize chemotherapy regimens for chemo-immunotherapy. J Thorac Dis, 14, 3648-3649, 2022
- Inamura K, Hamada T, Bullman S, Ugai T, Yachida S, Ogino S. Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. Gut, 2022
- Fukagawa E, Yuasa T, Inamura K, Hamada K, Fujiwara M, Komai Y, Yonese J. De novo large-cell neuroendocrine carcinoma of the prostate: A case report and literature review. IJU Case Rep, 5, 505-510, 2022
2021
- Yasuoka S, Yuasa T, Fujiwara M, Fujisaki J, Inamura K, Komai Y, Numao N, Yamamoto S, Yonese J. Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy. IJU Case Rep, 4, 136-138, 2021
- Yamamoto T, Gulanbar A, Hayashi K, Kohno A, Komai Y, Yonese J, Matsueda K, Inamura K. Is hypervascular papillary renal cell carcinoma present? Abdom Radiol (NY), 46, 1687-1693, 2021
- Une M, Takemura K,Inamura K, Fukushima H, Ito M, Kobayashi S, Yuasa T, Yonese J, Board P G, Koga F. Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. Cancers (Basel), 13, 5587, 2021
- Ohmoto A, Shigematsu Y, Fukuda N, Wang X, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Komai Y, Numao N, Yuasa T, Yonese J, Tomomatsu J, Inamura K, Takahashi S. Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. Endocr J, 68, 1383-1390, 2021
- Inamura K. Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. Semin Cancer Biol, 70, 11-23, 2021
- Inamura K. Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer. JAMA Oncol, 7, 637-638, 2021
- Furukawa T, Ozaka M, Takamatsu M, Takazawa Y, Inamura K, Inoue Y, Mie T, Takeda T, Kanata R, Kasuga A, Matsuyama M, Sasaki T, Takahashi Y, Sasahira N. Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms. Int J Surg Pathol, 29, 475-481, 2021
- Amori G, Sugawara E, Shigematsu Y, Akiya M, Kunieda J, Yuasa T, Yamamoto S, Yonese J, Takeuchi K, Inamura K. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer Prostatic Dis, 24, 767-774, 2021
2020
- Wakejima R, Inamura K, Ninomiya H, Nagano H, Mun M, Okumura S, Okubo K, Ishikawa Y. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma. Pathol Int, 70, 72-83, 2020
- Takemura K, Yuasa T, Inamura K, Amori G, Koga F, Board P G, Yonese J. Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Target Oncol, 15, 347-356, 2020
- Sano Y, Fujiwara M, Yuasa T, Komai Y, Yamamoto T, Kohno A, Nakao M, Inamura K, Yonese J. Testicular seminoma with a progressing pulmonary nodule and mediastinal lymphadenopathy without retroperitoneal metastasis. IJU Case Rep, 3, 211-214, 2020
- Sakakibara R, Kobayashi M, Takahashi N, Inamura K, Ninomiya H, Wakejima R, Kitazono S, Yanagitani N, Horiike A, Ichinose J, Matsuura Y, Nakao M, Mun M, Nishio M, Okumura S, Motoi N, Ito T, Miyazaki Y, Inase N, Ishikawa Y. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. Am J Surg Pathol, 44, 757-764, 2020
- Nakashima Y, Inamura K, Ninomiya H, Okumura S, Mun M, Kirimura S, Kobayashi M, Okubo K, Ishikawa Y. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma. Lung Cancer, 148, 20-27, 2020
- Naito K, Shigematsu Y, Fujiwara Y, Inamura K, Togashi Y, Inoue Y, Takazawa Y, Kanda H, Matsueda K. Identification of a specific ultrasonographic finding for differentiating hepatic angiomyolipoma from hepatocellular carcinoma. Clin Imaging, 59, 104-108, 2020
- Matsuda M, Ninomiya H, Wakejima R, Inamura K, Okumura S, Mun M, Kitagawa M, Ishikawa Y. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma. Pathol Res Pract, 216, 152817, 2020
- Inamura K. Roles of microbiota in response to cancer immunotherapy. Semin Cancer Biol, 65, 164-175, 2020
- Inamura K. Ethical Considerations about Genomic Medicine Implementation: Lessons Learned from the eMERGE III Study. J Pers Med, 10, 195, 2020
- Fujiwara R, Inamura K, Yuasa T, Numao N, Yamamoto S, Masuda H, Kawauchi A, Takeuchi K, Yonese J. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. Int J Clin Oncol, 25, 151-157, 2020
2019
- Yamamoto T, Koizumi M, Kohno A, Numao N, Inamura K. A case report on 111In chloride bone marrow scintigraphy in management of adrenal myelolipoma. Medicine (Baltimore), 98, e14625, 2019
- Wasserman I, Lee L H, Ogino S, Marco M R, Wu C, Chen X, Datta J, Sadot E, Szeglin B, Guillem J G, Paty P B, Weiser M R, Nash G M, Saltz L, Barlas A, Manova-Todorova K, Uppada S P B, Elghouayel A E, Ntiamoah P, Glickman J N, Hamada T, Kosumi K, Inamura K, Chan A T, Nishihara R, Cercek A, Ganesh K, Kemeny N E, Dhawan P, Yaeger R, Sawyers C L, Garcia-Aguilar J, Giannakis M, Shia J, Smith J J. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clin Cancer Res, 25, 1948-1956, 2019
- Muto M, Inamura K, Ninomiya H, Okumura S, Kitagawa M, Ishikawa Y. Pulmonary adenocarcinoma with mucin production and possible subtyping based on driver mutations and transcription factors. Journal of Medical and Dental Sciences, 66, 1-12, 2019
- Inamura K, Amori G, Yuasa T, Yamamoto S, Yonese J, Ishikawa Y. Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma. Cancer Manag Res, 11, 7021-7030, 2019
- Inamura I, Inamura K, Jinbo Y, Mihara T, Sasaoka Y. Preparation of metal phthalocyanine (MPc)-polymer complexes: the possible anti-cancer properties of FePc-polymer complexes. Heliyon, 5, e01383, 2019
- Hashimoto H, Usui G, Tsugeno Y, Sugita K, Amori G, Morikawa T,Inamura K . Cerebral Thromboembolism after Lobectomy for Lung Cancer: Pathological Diagnosis and Mechanism of Thrombus Formation. Cancers (Basel), 11, 488, 2019
- Hashimoto H, Tsugeno Y, Sugita K, Inamura K. Mesenchymal tumors of the lung: diagnostic pathology, molecular pathogenesis, and identified biomarkers. J Thorac Dis, 11, S9-s24, 2019
- Haga Y, Uemura M, Baba S, Inamura K, Takeuchi K, Nonomura N, Ueda K. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA. Anal Chem, 91, 2247-2254, 2019
2018
- Sugiura Y, Kanda H, Motoi N, Nomura K, Inamura K, Okada E, Matsumoto H, Shimoji T, Matsumoto S, Nakayama J, Takazawa Y, Ishikawa Y, Machinami R. Osteosarcoma arising in fibrous dysplasia, confirmed by mutational analysis of GNAS gene. Pathol Res Pract, 214, 318-324, 2018
- Subat S, Inamura K, Ninomiya H, Nagano H, Okumura S, Ishikawa Y. Unique MicroRNA and mRNA Interactions in EGFR-Mutated Lung Adenocarcinoma. J Clin Med, 7, 419, 2018
- Shigematsu Y, Inamura K, Yamamoto N, Mise Y, Saiura A, Ishikawa Y, Takahashi S, Kanda H. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer, 18, 980, 2018
- Shigematsu Y, Inamura K, Mise Y, Saiura A, Rehnberg E, Yamamoto N, Ishikawa Y, Takahashi S, Kanda H. CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan. Oncotarget, 9, 17056-17065, 2018
- Shigematsu Y, Inamura K. Gut microbiome: a key player in cancer immunotherapy. Hepatobiliary Surg Nutr, 7, 479-480, 2018
- Noma D, Inamura K, Matsuura Y, Hirata Y, Nakajima T, Yamazaki H, Hirai Y, Ichinose J, Nakao M, Ninomiya H, Mun M, Nakagawa K, Masuda M, Ishikawa Y, Okumura S. Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer. Clin Lung Cancer, 19, e109-e122, 2018
- Koh H, Hamada T, Song M, Liu L, Cao Y, Nowak J A, da Silva A, Twombly T, Morikawa T, Kim S A, Masugi Y, Kosumi K, Shi Y, Gu M, Li W, Du C, Chen Y, Li W, Liu H, Li C, Wu K, Nosho K, Inamura K, Hanyuda A, Zhang X, Giannakis M, Chan A T, Fuchs C S, Nishihara R, Meyerhardt J A, Ogino S. Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells. JNCI Cancer Spectr, 2, pky058, 2018
- Inamura K, Takazawa Y, Inoue Y, Yokouchi Y, Kobayashi M, Saiura A, Shibutani T, Ishikawa Y. Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. J Clin Med, 7, 172, 2018
- Inamura K, Shigematsu Y, Ninomiya H, Nakashima Y, Kobayashi M, Saito H, Takahashi K, Futaya E, Okumura S, Ishikawa Y, Kanda H. CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining. Cancers (Basel), 10, 252, 2018
- Inamura K. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers (Basel), 10, 26, 2018
- Inamura K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers (Basel), 10, 72, 2018
- Inamura K. Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget, 9, 14723-14737, 2018
- Inamura K. Bladder Cancer: New Insights into Its Molecular Pathology. Cancers (Basel), 10, 100, 2018
- Inamura K. Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. Int J Mol Sci, 19, 1259, 2018
- Hamada T, Zhang X, Mima K, Bullman S, Sukawa Y, Nowak J A, Kosumi K, Masugi Y, Twombly T S, Cao Y, Song M, Liu L, da Silva A, Shi Y, Gu M, Li W, Koh H, Nosho K, Inamura K, Keum N, Wu K, Meyerhardt J A, Kostic A D, Huttenhower C, Garrett W S, Meyerson M, Giovannucci E L, Chan A T, Fuchs C S, Nishihara R, Giannakis M, Ogino S. Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res, 6, 1327-1336, 2018
- Hamada T, Soong T R, Masugi Y, Kosumi K, Nowak J A, da Silva A, Mu X J, Twombly T S, Koh H, Yang J, Song M, Liu L, Gu M, Shi Y, Nosho K, Morikawa T,Inamura K, Shukla S A, Wu C J, Garraway L A, Zhang X, Wu K, Meyerhardt J A, Chan A T, Glickman J N, Rodig S J, Freeman G J, Fuchs C S, Nishihara R, Giannakis M, Ogino S. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology, 7, e1442999, 2018
- Hamada T, Liu L, Nowak J A, Mima K, Cao Y, Ng K, Twombly T S, Song M, Jung S, Dou R, Masugi Y, Kosumi K, Shi Y, da Silva A, Gu M, Li W, Keum N, Wu K, Nosho K, Inamura K, Meyerhardt J A, Nevo D, Wang M, Giannakis M, Chan A T, Giovannucci E L, Fuchs C S, Nishihara R, Zhang X, Ogino S. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer, 103, 98-107, 2018
- Grasso C S, Giannakis M, Wells D K, Hamada T, Mu X J, Quist M, Nowak J A, Nishihara R, Qian Z R, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels M S, Grady W M, Hsu L, Hu-Lieskovan S, Huyghe J R, Kim Y J, Krystofinski P, Leiserson M D M, Montoya D J, Nadel B B, Pellegrini M, Pritchard C C, Puig-Saus C, Quist E H, Raphael B J, Salipante S J, Shin D S, Shinbrot E, Shirts B, Shukla S, Stanford J L, Sun W, Tsoi J, Upfill-Brown A, Wheeler D A, Wu C J, Yu M, Zaidi S H, Zaretsky J M, Gabriel S B, Lander E S, Garraway L A, Hudson T J, Fuchs C S, Ribas A, Ogino S, Peters U. Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov, 8, 730-749, 2018
2017
- Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Matsuura Y, Nakao M, Mun M, Okumura S, Inase N, Nishio M, Motoi N, Ishikawa Y. EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. Clin Lung Cancer, 18, 527-534.e1, 2017
- Muto M, Inamura K, Ozawa N, Endo T, Masuda H, Yonese J, Ishikawa Y. Skene's gland adenocarcinoma with intestinal differentiation: A case report and literature review. Pathol Int, 67, 575-579, 2017
- Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak J A, Liao X, Nosho K, Chan A T, Giannakis M, Bass A J, Hodi F S, Freeman G J, Rodig S, Fuchs C S, Qian Z R, Ogino S. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut, 66, 1463-1473, 2017
- Masugi Y, Nishihara R, Hamada T, Song M, da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, Nevo D, Inamura K, Cao Y, Liao X, Nosho K, Chan A T, Giannakis M, Bass A J, Hodi F S, Freeman G J, Rodig S J, Fuchs C S, Qian Z R, Nowak J A, Ogino S. Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunol Res, 5, 1046-1055, 2017
- Liu L, Nishihara R, Qian Z R, Tabung F K, Nevo D, Zhang X, Song M, Cao Y, Mima K, Masugi Y, Shi Y, da Silva A, Twombly T, Gu M, Li W, Hamada T, Kosumi K,Inamura K, Nowak J A, Drew D A, Lochhead P, Nosho K, Wu K, Wang M, Garrett W S, Chan A T, Fuchs C S, Giovannucci E L, Ogino S. Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor. Gastroenterology, 153, 1517-1530.e14, 2017
- Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer, 103, 44-51, 2017
- Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget, 8, 28725-28735, 2017
- Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Nishio M, Okumura S, Ishikawa Y. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. Cancer Med, 6, 2347-2356, 2017
- Inamura K, Kobayashi M, Nagano H, Sugiura Y, Ogawa M, Masuda H, Yonese J, Ishikawa Y. A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder. Hum Pathol, 69, 96-100, 2017
- Inamura K. Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer. Cancers (Basel), 9, 49, 2017
- Inamura K. Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer. Cells, 6, 12, 2017
- Inamura K. Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features. Cancers (Basel), 9, 111, 2017
- Inamura K. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol, 7, 193, 2017
- Inamura K. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci, 18, 2195, 2017
2016
- Song M, Nishihara R, Wang M, Chan A T, Qian Z R, Inamura K, Zhang X, Ng K, Kim S A, Mima K, Sukawa Y, Nosho K, Fuchs C S, Giovannucci E L, Wu K, Ogino S. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut, 65, 296-304, 2016
- Song M, Nishihara R, Cao Y, Chun E, Qian Z R, Mima K, Inamura K, Masugi Y, Nowak J A, Nosho K, Wu K, Wang M, Giovannucci E, Garrett W S, Fuchs C S, Ogino S, Chan A T. Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells. JAMA Oncol, 2, 1197-206, 2016
- Qian Z R, Li T, Ter-Minassian M, Yang J, Chan J A, Brais L K, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim S A, Mima K, Sukawa Y, Dou R, Lin X, Christiani D C, Schmidlin F, Fuchs C S, Mahmood U, Ogino S, Kulke M H. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas, 45, 1386-1393, 2016
- Noma D,Inamura K, Mun M, Terauchi T, Matsuura Y, Nakao M, Ninomiya H, Nakagawa K, Masuda M, Okumura S, Ishikawa Y. Thymic oncocytic carcinoid with a markedly elevated level of maximum SUV. Pathol Int, 66, 593-595, 2016
- Mima K, Nishihara R, Nowak J A, Kim S A, Song M, Inamura K, Sukawa Y, Masuda A, Yang J, Dou R, Nosho K, Baba H, Giovannucci E L, Bowden M, Loda M, Giannakis M, Bass A J, Dranoff G, Freeman G J, Chan A T, Fuchs C S, Qian Z R, Ogino S. MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res, 4, 33-40, 2016
- McCleary N J, Sato K, Nishihara R,Inamura K, Morikawa T, Zhang X, Wu K, Yamauchi M, Kim S A, Sukawa Y, Mima K, Qian Z R, Fuchs C S, Ogino S, Meyerhardt J A. Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clin Cancer Res, 22, 1489-98, 2016
- Kim S A, Inamura K, Yamauchi M, Nishihara R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald K C, Fuchs C S, Wu K, Chan A T, Zhang X, Ogino S, Qian Z R. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer, 114, 199-206, 2016
- Inamura K, Yokouchi Y, Sakakibara R, Kobayashi M, Subat S, Ninomiya H, Nagano H, Nomura K, Okumura S, Ishikawa Y. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. Jpn J Clin Oncol, 46, 935-941, 2016
- Inamura K, Song M, Jung S, Nishihara R, Yamauchi M, Lochhead P, Qian Z R, Kim S A, Mima K, Sukawa Y, Masuda A, Imamura Y, Zhang X, Pollak M N, Mantzoros C S, Harris C C, Giovannucci E, Fuchs C S, Cho E, Chan A T, Wu K, Ogino S. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. J Natl Cancer Inst, 1082016
- Inamura K, Ishikawa Y. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med, 5, 36, 2016
- Hanyuda A, Ogino S, Qian Z R, Nishihara R, Song M, Mima K, Inamura K, Masugi Y, Wu K, Meyerhardt J A, Chan A T, Fuchs C S, Giovannucci E L, Cao Y. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer, 139, 854-68, 2016
- Hanyuda A, Kim S A, Martinez-Fernandez A, Qian Z R, Yamauchi M, Nishihara R, Morikawa T, Liao X, Inamura K, Mima K, Cao Y, Zhang X, Wu K, Chan A T, Giovannucci E L, Meyerhardt J A, Fuchs C S, Shivdasani R A, Ogino S. Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. Ann Surg Oncol, 23, 908-17, 2016
- Giannakis M, Mu X J, Shukla S A, Qian Z R, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak J A, Lawrence M S, Giovannucci E L, Chan A T, Ng K, Meyerhardt J A, Van Allen E M, Getz G, Gabriel S B, Lander E S, Wu C J, Fuchs C S, Ogino S, Garraway L A. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep, 15, 857-865, 2016
- Cao Y, Nishihara R, Qian Z R, Song M, Mima K, Inamura K, Nowak J A, Drew D A, Lochhead P, Nosho K, Morikawa T, Zhang X, Wu K, Wang M, Garrett W S, Giovannucci E L, Fuchs C S, Chan A T, Ogino S. Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology, 151, 879-892.e4, 2016
2015
- Tu H C, Schwitalla S, Qian Z, LaPier G S, Yermalovich A, Ku Y C, Chen S C, Viswanathan S R, Zhu H, Nishihara R,Inamura K, Kim S A, Morikawa T, Mima K, Sukawa Y, Yang J, Meredith G, Fuchs C S, Ogino S, Daley G Q. LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes Dev, 29, 1074-86, 2015
- Song M, Nishihara R, Wu K, Qian Z R, Kim S A, Sukawa Y, Mima K, Inamura K, Masuda A, Yang J, Fuchs C S, Giovannucci E L, Ogino S, Chan A T. Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. J Natl Cancer Inst, 1072015
- Sato S, Motoi N, Hiramatsu M, Miyauchi E, Ono H, Saito Y, Nagano H, Ninomiya H, Inamura K, Uehara H, Mun M, Sakao Y, Okumura S, Tsuchida M, Ishikawa Y. Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. Am J Surg Pathol, 39, 912-21, 2015
- Mima K, Sukawa Y, Nishihara R, Qian Z R, Yamauchi M, Inamura K, Kim S A, Masuda A, Nowak J A, Nosho K, Kostic A D, Giannakis M, Watanabe H, Bullman S, Milner D A, Harris C C, Giovannucci E, Garraway L A, Freeman G J, Dranoff G, Chan A T, Garrett W S, Huttenhower C, Fuchs C S, Ogino S. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol, 1, 653-61, 2015
- Lochhead P, Nishihara R, Qian Z R, Mima K, Cao Y, Sukawa Y, Kim S A,Inamura K, Zhang X, Wu K, Giovannucci E, Meyerhardt J A, Chan A T, Fuchs C S, Ogino S. Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. Am J Clin Nutr, 102, 1134-41, 2015
- Inamura K, Yamauchi M, Nishihara R, Kim S A, Mima K, Sukawa Y, Li T, Yasunari M, Zhang X, Wu K, Meyerhardt J A, Fuchs C S, Harris C C, Qian Z R, Ogino S. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol, 22, 1226-1235, 2015
- Hiyoshi Y, Schetter A J, Okayama H, Inamura K, Anami K, Nguyen G H, Horikawa I, Hawkes J E, Bowman E D, Leung S Y, Harris C C. Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. PLoS One, 10, e0124899, 2015
2014
- Nishihara R, Wang M, Qian Z R, Baba Y, Yamauchi M, Mima K, Sukawa Y, Kim S A, Inamura K, Zhang X, Wu K, Giovannucci E L, Chan A T, Fuchs C S, Ogino S, Schernhammer E S. Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. Am J Clin Nutr, 100, 1479-88, 2014
- Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim S A, Mima K, Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt J A, Chan A T, Fuchs C S, Ogino S, Qian Z R. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Ann Surg Oncol, 21, 4164-73, 2014
- Jung S, Qian Z R, Yamauchi M, Bertrand K A, Fitzgerald K C, Inamura K, Kim S A, Mima K, Sukawa Y, Zhang X, Wang M, Smith-Warner S A, Wu K, Fuchs C S, Chan A T, Giovannucci E L, Ng K, Cho E, Ogino S, Nishihara R. Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. Cancer Epidemiol Biomarkers Prev, 23, 1628-37, 2014
- Inamura K, Yamauchi M, Nishihara R, Lochhead P, Qian Z R, Kuchiba A, Kim S A, Mima K, Sukawa Y, Jung S, Zhang X, Wu K, Cho E, Chan A T, Meyerhardt J A, Harris C C, Fuchs C S, Ogino S. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst, 1062014
- Inamura K, Ninomiya H, Nomura K, Tsuchiya E, Satoh Y, Okumura S, Nakagawa K, Takata A, Kohyama N, Ishikawa Y. Combined effects of asbestos and cigarette smoke on the development of lung adenocarcinoma: different carcinogens may cause different genomic changes. Oncol Rep, 32, 475-82, 2014
- Hamanaka W, Motoi N, Ishikawa S, Ushijima M, Inamura K, Hatano S, Uehara H, Okumura S, Nakagawa K, Nishio M, Horai T, Aburatani H, Matsuura M, Iwasaki A, Ishikawa Y. A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy. Hum Pathol, 45, 1045-56, 2014
2013
- Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian Z R, Inamura K, Kim S A, Kuchiba A, Yamauchi M, Imamura Y, Willett W C, Rosner B A, Fuchs C S, Giovannucci E, Ogino S, Chan A T. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med, 369, 1095-105, 2013
- Ninomiya H, Kato M, Sanada M, Takeuchi K,Inamura K, Motoi N, Nagano H, Nomura K, Sakao Y, Okumura S, Mano H, Ogawa S, Ishikawa Y. Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. BMC Cancer, 13, 8, 2013
2012
- Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, Yamamoto S, Yonese J, Fukui I, Ishikawa Y. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol, 36, 35-42, 2012
- Fujiwara T, Hiramatsu M, Isagawa T, Ninomiya H, Inamura K, Ishikawa S, Ushijima M, Matsuura M, Jones M H, Shimane M, Nomura H, Ishikawa Y, Aburatani H. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis. Lung Cancer, 75, 119-25, 2012
2011
- Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikwa Y, Fukui I. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. Urology, 77, 831-5, 2011
- Inamura K, Kumasaka T, Furuta R, Shimada K, Hiyama N, Furuhata Y, Tanaka I, Takemura T. Mixed squamous cell and glandular papilloma of the lung: a case study and literature review. Pathol Int, 61, 252-8, 2011
2010
- Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med, 134, 66-72, 2010
- Inamura K, Ishikawa Y. Lung cancer progression and metastasis from the prognostic point of view. Clin Exp Metastasis, 27, 389-97, 2010
- Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer, 70, 94-102, 2010
2009
- Takeuchi K, Choi Y L, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res, 15, 3143-9, 2009
- Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T, Okumura S, Satoh Y, Nakagawa K, Nishio M, Horai T, Miyata S, Tsuchiya E, Fukayama M, Ishikawa Y. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer, 63, 235-40, 2009
- Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun M Y, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi Y L, Mano H, Ishikawa Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol, 22, 508-15, 2009
2008
- Takeuchi K, Choi Y L, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res, 14, 6618-24, 2008
- Inamura K, Togashi Y, Ninomiya H, Shimoji T, Noda T, Ishikawa Y. HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells. Anticancer Res, 28, 2121-7, 2008
- Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi Y L, Niki T, Mano H, Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol, 3, 13-7, 2008
- Choi Y L, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res, 68, 4971-6, 2008
2007
- Inamura K, Togashi Y, Okui M, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Shimoji T, Noda T, Ishikawa Y. HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas. J Thorac Oncol, 2, 802-7, 2007
- Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y. let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer, 58, 392-6, 2007
- Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Okui M, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Ishikawa Y. Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. Lung Cancer, 57, 201-6, 2007
- Inamura K, Shimoji T, Ninomiya H, Hiramatsu M, Okui M, Satoh Y, Okumura S, Nakagawa K, Noda T, Fukayama M, Ishikawa Y. A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity. Hum Pathol, 38, 702-9, 2007
2006
- Satoh Y, Hoshi R, Tsuzuku M, Ishikawa Y, Inamura K, Horai T. Cytology of pulmonary adenocarcinomas showing enteric differentiation. Acta Cytol, 50, 250-6, 2006
- Inamura K, Furuta R, Satoh Y, Shirakawa T, Okumura S, Nakagawa K, Fujiwara M, Tsuchiya E, Ishikawa Y. Loss of Chromosome 13q is Associated with Malignant Potential in Pulmonary Carcinoids. Cancer Genomics Proteomics, 3, 39-45, 2006
2005
- Satoh Y, Ishikawa Y,Inamura K, Okumura S, Nakagawa K, Tsuchiya E. Classification of parietal pleural invasion at adhesion sites with surgical specimens of lung cancer and implications for prognosis. Virchows Arch, 447, 984-9, 2005
- Inamura K, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Fukayama M, Ishikawa Y. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol, 29, 660-5, 2005
- Inamura K, Fujiwara T, Hoshida Y, Isagawa T, Jones M H, Virtanen C, Shimane M, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Ishikawa S, Aburatani H, Nomura H, Ishikawa Y. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene, 24, 7105-13, 2005